DF
Highly rated in
8
conditions
Highly rated in
8
conditions
Check Dr. Debra L. Friedman's experience treating your condition:
About Dr. Debra L. Friedman

Debra Friedman is a Pediatric Hematologist Oncology specialist and a Hematologist in Nashville, Tennessee. Friedman has been practicing medicine for over 31 years and is highly rated in 8 conditions, according to our data. Her top areas of expertise are Hodgkin Lymphoma, Retinoblastoma, Classical Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. She is licensed to treat patients in Tennessee and Washington. Friedman is currently accepting new patients.

Her clinical research consists of co-authoring 148 peer reviewed articles and participating in 31 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Debra L. Friedman it is best to call her office and ask if your insurance is accepted.


Dr. Debra L. Friedman accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter
  •  Cigna
  •  Alliant Health

Call to see if your plan is accepted.
Locations
2200 Childrens Way, Nashville, TN 37232
Background & Education
Graduate Institution
UMDNJ-New Jersey Medical School, 1991
Specialties
Pediatric Hematology Oncology
Hematology
Oncology
Licenses
Pediatric Hematology-Oncology in WA
Hospital Affiliations
Baptist Health Deaconess Madisonville
Vanderbilt University Medical Center
Languages Spoken
English
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


30 Clinical Trials

Expanding Rural Health Cancer Control Capacity: Focus on Cancer Survivorship
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enhancing Cancer Care Of Rural Dwellers Through Telehealth and Engagement (ENCORE)
A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Key Adverse Events After Childhood Cancer
Umbrella Long-Term Follow-Up Protocol
Research Into Visual Endpoints and RB Health Outcomes After Treatment (RIVERBOAT)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
Health-Related Outcomes For Hodgkin's Disease Survivors
A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
Navigated Early Survivorship Transition in Improving Survivorship Care Planning in Patients With Newly Diagnosed Cancer and Their Caregivers (NEST)
Radiation Sensitivity, DNA Repair, and Second Cancers.
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Trial of Systemic Neoadjuvant Chemotherapy for Group B Intraocular Retinoblastoma
Longitudinal Assessment of Ovarian Reserve in Adolescents With Lymphoma
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
Yoga Intervention for Cancer Survivors
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
View 20 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors